Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 13
2009 9
2010 20
2011 27
2012 31
2013 46
2014 53
2015 63
2016 64
2017 59
2018 57
2019 65
2020 80
2021 20
Text availability
Article attribute
Article type
Publication date

Search Results

536 results
Results by year
Filters applied: . Clear all
Page 1
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.
Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW. Tse C, et al. Cancer Res. 2008 May 1;68(9):3421-8. doi: 10.1158/0008-5472.CAN-07-5836. Cancer Res. 2008. PMID: 18451170 Free article.
The oral bioavailability of ABT-263 in preclinical animal models is 20% to 50%, depending on formulation. ...In human tumor cells, ABT-263 induces Bax translocation, cytochrome c release, and subsequent apoptosis. ...
The oral bioavailability of ABT-263 in preclinical animal models is 20% to 50%, depending on formulation. ...In human tumor ce …
ABT-263 exhibits apoptosis-inducing potential in oral cancer cells by targeting C/EBP-homologous protein.
Yang IH, Jung JY, Kim SH, Yoo ES, Cho NP, Lee H, Lee JY, Hong SD, Shin JA, Cho SD. Yang IH, et al. Cell Oncol (Dordr). 2019 Jun;42(3):357-368. doi: 10.1007/s13402-019-00431-5. Epub 2019 Mar 27. Cell Oncol (Dordr). 2019. PMID: 30919222
PURPOSE: ABT-263 is a potent BH3 mimetic that possesses anticancer potential against various types of cancer. ...RESULTS: We found that ABT-263 suppressed viability and induced apoptosis in human oral cancer-derived cell lines HSC-3 and HSC-4. ...
PURPOSE: ABT-263 is a potent BH3 mimetic that possesses anticancer potential against various types of cancer. ...RESULTS: We f …
Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis.
Lagares D, Santos A, Grasberger PE, Liu F, Probst CK, Rahimi RA, Sakai N, Kuehl T, Ryan J, Bhola P, Montero J, Kapoor M, Baron M, Varelas X, Tschumperlin DJ, Letai A, Tager AM. Lagares D, et al. Sci Transl Med. 2017 Dec 13;9(420):eaal3765. doi: 10.1126/scitranslmed.aal3765. Sci Transl Med. 2017. PMID: 29237758
Myofibroblasts become particularly susceptible to apoptosis induced by "BH3 mimetic" drugs inhibiting BCL-X(L) such as ABT-263. ABT-263 displaces BCL-X(L) binding to BIM, allowing BIM to activate apoptosis on stiffness-primed myofibroblasts. Therapeuti …
Myofibroblasts become particularly susceptible to apoptosis induced by "BH3 mimetic" drugs inhibiting BCL-X(L) such as ABT-263
ABT-263-induced MCL1 upregulation depends on autophagy-mediated 4EBP1 downregulation in human leukemia cells.
Lee YC, Wang LJ, Huang CH, Shi YJ, Chang LS. Lee YC, et al. Cancer Lett. 2018 Sep 28;432:191-204. doi: 10.1016/j.canlet.2018.06.019. Epub 2018 Jun 15. Cancer Lett. 2018. PMID: 29913235
The present study aimed to investigate the pathway related to MCL1 expression in ABT-263-treated human leukemia U937 cells. ABT-263 upregulated MCL1 protein expression but did not affect its mRNA level and protein stability. Notably, ABT-263
The present study aimed to investigate the pathway related to MCL1 expression in ABT-263-treated human leukemia U937 cells. …
Cellular Senescence: A Translational Perspective.
Kirkland JL, Tchkonia T. Kirkland JL, et al. EBioMedicine. 2017 Jul;21:21-28. doi: 10.1016/j.ebiom.2017.04.013. Epub 2017 Apr 12. EBioMedicine. 2017. PMID: 28416161 Free PMC article. Review.
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW. Souers AJ, et al. Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6. Nat Med. 2013. PMID: 23291630
However, concomitant on-target thrombocytopenia caused by BCL-X(L) inhibition limits the efficacy achievable with this agent. Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and BCL-2-selective inhibitor, ABT-199. This …
However, concomitant on-target thrombocytopenia caused by BCL-X(L) inhibition limits the efficacy achievable with this agent. Here we report …
ABT-263 induces G(1)/G(0)-phase arrest, apoptosis and autophagy in human esophageal cancer cells in vitro.
Lin QH, Que FC, Gu CP, Zhong DS, Zhou D, Kong Y, Yu L, Liu SW. Lin QH, et al. Acta Pharmacol Sin. 2017 Dec;38(12):1632-1641. doi: 10.1038/aps.2017.78. Epub 2017 Jul 10. Acta Pharmacol Sin. 2017. PMID: 28713162 Free PMC article.
But the anticancer mechanisms of ABT-263 have not been fully elucidated. In this study we investigated the effects of ABT-263 on human esophageal cancer cells in vitro and to explore its anticancer mechanisms. ...Knockdown of p21(Waf1/Cip1) attenuated …
But the anticancer mechanisms of ABT-263 have not been fully elucidated. In this study we investigated the effects of ABT
Allosteric modulation of sigma receptors by BH3 mimetics ABT-737, ABT-263 (Navitoclax) and ABT-199 (Venetoclax).
Lever JR, Fergason-Cantrell EA. Lever JR, et al. Pharmacol Res. 2019 Apr;142:87-100. doi: 10.1016/j.phrs.2019.01.040. Epub 2019 Feb 3. Pharmacol Res. 2019. PMID: 30721730
ABT-737, ABT-263 (Navitoclax) and ABT-199 (Venetoclax) are under intensive preclinical and clinical investigation as treatments for hematologic and other malignancies. ...Negative allosteric modulation of [(3)H](+)-pentazocine, an agonist, bindi
ABT-737, ABT-263 (Navitoclax) and ABT-199 (Venetoclax) are under intensive preclinical and clinical inves
Intracellular levels of reactive oxygen species correlate with ABT-263 sensitivity in non-small-cell lung cancer cells.
Ohgino K, Terai H, Yasuda H, Nukaga S, Hamamoto J, Tani T, Kuroda A, Arai D, Ishioka K, Masuzawa K, Ikemura S, Kawada I, Naoki K, Fukunaga K, Soejima K. Ohgino K, et al. Cancer Sci. 2020 Oct;111(10):3793-3801. doi: 10.1111/cas.14569. Epub 2020 Aug 5. Cancer Sci. 2020. PMID: 32687646 Free PMC article.
ABT-263 (Navitoclax) is a BH3-mimetic drugs targeting anti-apoptotic B-cell lymphoma-2 (BCL-2) family proteins, including BCL-2, BCL-xL, and BCL-w, thereby inducing apoptosis. In small-cell lung cancer (SCLC) cells, the response to ABT-263 is as
ABT-263 (Navitoclax) is a BH3-mimetic drugs targeting anti-apoptotic B-cell lymphoma-2 (BCL-2) family proteins, includi
Inhibition of EGFR pathway promotes the cytotoxicity of ABT-263 in human leukemia K562 cells by blocking MCL1 upregulation.
Lee YC, Wang LJ, Huang CH, Chiou JT, Shi YJ, Chang LS. Lee YC, et al. Biochem Pharmacol. 2020 Aug;178:114047. doi: 10.1016/j.bcp.2020.114047. Epub 2020 May 22. Biochem Pharmacol. 2020. PMID: 32446890
ABT-263 induces MCL1 upregulation in cancer cells, which confers resistance to the drug. ...Treatment with EGFR inhibitors mitigated MCL1 upregulation induced by ABT-263. Additionally, lithium chloride (LiCl) alleviated ABT-263-induced MC
ABT-263 induces MCL1 upregulation in cancer cells, which confers resistance to the drug. ...Treatment with EGFR inhibitors mit
536 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page